IDEXX Sets Stage for Q2 Results and Investor Day Amid Strong Growth

WESTBROOK, ME – July 01, 2026 – IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, is poised for a significant period of investor engagement. The company has announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, before the market opens. Shortly after, it will host its highly anticipated 2026 Investor Day on Thursday, August 13, at its corporate headquarters.

These back-to-back events will provide a comprehensive look into the company's recent performance and its long-term strategic vision. For investors and analysts, the disclosures will serve not only as a report card on IDEXX's execution but also as a crucial barometer for the health of the broader pet care industry, which has shown remarkable resilience and growth.

A Bellwether for the Pet Economy

As IDEXX prepares to unveil its Q2 2026 figures, the market will be watching closely for indicators of sustained momentum. The company is coming off a period of exceptionally strong performance. For the full year 2025, IDEXX reported revenues of $4.3 billion, a 10% organic increase, with earnings per share growing 14% on a comparable basis. This strength continued into the first quarter of 2026, which saw revenues of $1.14 billion—an 11% organic increase—and a 15% comparable EPS growth.

This robust performance has been powered by the enduring trend of pet humanization, where owners increasingly view pets as family members and are willing to invest more in their health and well-being. This has translated into higher spending on advanced diagnostics and veterinary care, directly benefiting IDEXX’s core business. The company's Companion Animal Group (CAG) Diagnostics recurring revenue has been a consistent engine of growth, expanding 12% organically in the first quarter of 2026.

Despite the positive top-line trends, the market will be looking for commentary on potential headwinds. Recent industry data, including from IDEXX's own reports, has noted a slight decline of approximately 1% in U.S. same-store clinical visits, particularly in the wellness category. While the company has so far successfully offset this through increased diagnostic utilization and innovation, investors will be keen to understand the persistence of this trend and the company's strategies to navigate it. The upcoming earnings call, scheduled for 8:30 a.m. ET on August 4, will be the first opportunity for analysts to probe these dynamics.

Innovation at the Core of Growth

IDEXX's financial success is not accidental; it is deeply rooted in a strategy of relentless innovation in diagnostics and software. The company has consistently brought new technologies to market that enhance veterinary practices by improving medical care, boosting efficiency, and enabling better client communication. This innovation pipeline has been a key differentiator in a competitive landscape.

One of the most significant recent successes has been the IDEXX inVue Dx™ cellular analyzer. Described as one of the most successful product launches in the company's history, the slide-free technology has seen phenomenal uptake. IDEXX placed over 1,900 units in the fourth quarter of 2025 and another 1,100 in the first quarter of 2026, exceeding initial expectations. This platform streamlines common cytology and morphology workflows, saving veterinarians valuable time. Revenue per unit is already meeting projections, with further upside anticipated as adoption of more advanced applications grows.

Beyond the inVue Dx™, the company continues to innovate across its portfolio. The IDEXX Cancer Dx™, a novel blood-based test for early detection of common canine cancers, has been well-received in North America and is now expanding into Europe and Australia. This test addresses a critical unmet need for non-invasive cancer screening. Furthermore, new specialty tests for the Catalyst® platform, such as for Pancreatic Lipase and Cortisol, continue to broaden the diagnostic capabilities available at the point of care. This commitment to R&D ensures that IDEXX remains at the forefront of veterinary medicine, driving both clinical advancements and its own financial growth.

Strategic Outlook and Investor Day Expectations

While the Q2 earnings will provide a snapshot of recent performance, the 2026 Investor Day on August 13 promises a deeper look into the company's future. This event is particularly timely, as it will offer a platform for the leadership team, including new CEO Michael Erickson who took the helm after Jay Mazelsky's successful tenure, to outline their long-term vision. Erickson is expected to emphasize a continued focus on diagnostics, software, and the integration of artificial intelligence to unlock new insights from the vast amount of data IDEXX processes.

Analysts and institutional investors, who can register to attend the event in person, will be looking for details on several key fronts. Topics of interest will likely include the company's long-term growth initiatives, its roadmap for the next wave of product innovation, and its strategy for global expansion. The event will also be an opportunity for management to address how IDEXX will continue to drive value for veterinary practices by integrating its diagnostic instruments with its cloud-native Practice Information Management Systems (PIMS), which have already seen double-digit growth in their installed base.

Analyst sentiment remains broadly positive heading into these events, with a consensus "Buy" rating and average 12-month price targets suggesting significant upside from current levels. Many analysts see IDEXX as a durable growth story with a wide competitive moat built on innovation, a massive installed base of instruments, and high customer retention rates. The Investor Day will be a critical opportunity for the company to reinforce this narrative and detail the specific strategies that will fuel its growth for years to come.

Investors and interested parties can access a live webcast of the Q2 2026 earnings conference call and the 2026 Investor Day presentations via the IDEXX investor relations website at www.idexx.com/investors. A replay of the earnings call will be available on the website after 1:00 p.m. ET on August 4. Those wishing to listen to the live earnings call by phone can dial 1-800-330-6730 or 1-213-279-1575 and use passcode 922025.